Class / Patent application number | Description | Number of patent applications / Date published |
514129000 | Oxygen bonded directly to a carbon or hydrogen and wherein the oxygen is not bonded directly to phosphorus | 54 |
20090170817 | CORROSION INHIBITION - The present invention relates to a method of preventing or alleviating the problems associated with corrosion and to novel formulations for use in such a method. | 07-02-2009 |
20090186858 | Synergistic compositions - A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale. | 07-23-2009 |
20090197840 | COMPOSITION AND METHOD FOR ENHANCING SKIN CELL GROWTH, PROLIFERATION AND REPAIR - A skin treatment composition is provided which contains calcium glycerophosphate and a fatty acid source derived from an animal or a vegetable. The composition enhances skin cell proliferation and growth and repair of damage to skin cells. Methods for enhancing skin cell repair, proliferation, and growth and for enhancing ceramide synthesis involve topically applying to the skin a composition containing calcium glycerophosphate and a fatty acid source derived from an animal or a vegetable. | 08-06-2009 |
20090203652 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES - The compounds of formula (I): | 08-13-2009 |
20090239830 | Treatment of viral infections by modulation of host cell metabolic pathways - Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated. | 09-24-2009 |
20100041630 | Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt - Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with inflammation. Therefore, methods are provided for treating or preventing an inflammatory condition using a glycerophosphate salt. In particular, methods are provided for treating or preventing an inflammatory condition using calcium glycerophosphate (CGP). | 02-18-2010 |
20100152141 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS - The invention relates to 5-HT | 06-17-2010 |
20100184725 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin - A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans. | 07-22-2010 |
20100210600 | Methods and Compositions for Treating Urogenital Disorders - Glycerophosphate salts have been found to drastically improve the treatment of urogenital disorders such as urethral strictures and vaginal atrophy. Methods, devices and kits are described for treating urogenital disorders using a composition comprising an effective amount of a glycerophosphate salt. | 08-19-2010 |
20100261681 | ALPHA-CHLORO AND ALPHA-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of a series of α-substituted methylene phosphonate analogs, in which the α-CH | 10-14-2010 |
20100298275 | Methods of and Formulations for Reducing and Inhibiting the Growth of the Concentration of Microbes in Water-Based Fluids and Systems Used with Them - The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use glutaraldehyde and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C | 11-25-2010 |
20100305071 | METHODS FOR IMPROVING HEALING OF AN ORAL LESION USING A GLYCEROPHOSPHATE SALT - Glycerophosphate salts have been found to hasten the healing and rapid scaling of lesions of the mouth. Methods are provided for improving healing of an oral lesion or preventing diseases or conditions related to an oral lesion using a glycerophosphate salt. In particular, methods are provided for preventing diseases or conditions related to an oral lesion using calcium glycerophosphate (CGP). | 12-02-2010 |
20110053896 | OSMOLYTES FOR THE TREATMENT OF ALLERGIC OR VIRAL RESPIRATORY DISEASES - The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances , more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1, 3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds. | 03-03-2011 |
20110065674 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - The invention relates to methods and compositions for improving cognitive function by using a combination of valproic acid and analogs and derivatives thereof (“valproate”) and an acetylcholinesterase inhibitor (AChEI). In particular, it relates to the use of a combination of a valproate and an AChEI in treating age-related cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-Associated Memory Impairment (AAMI) or Age-Related Cognitive Decline (ARCD). | 03-17-2011 |
20110195938 | PROCESS FOR PREVENTING OR MITIGATING BIOFOULING - Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some applications, may also inhibit biofouling. | 08-11-2011 |
20110212928 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment. | 09-01-2011 |
20110230449 | Alkoxylated Phosphoric Acid Triesters With A High Degree Of Alkoxylation - The invention relates to alkoxylated phosphoric acid triesters of formula (I) wherein x, y and z respectively stand for a number between 51 and 200. The alkoxylated phosphoric acid triesters of formula (I) are characterised especially by advantageous thickening properties. | 09-22-2011 |
20110230450 | PLATELET-ACTIVATING FACTOR (PAF) ANALOGS AND USES THEREOF - Disclosed are novel methods and compositions for treating inflammatory diseases and disorders, utilizing structural analogs of platelet activating factor (PAF). | 09-22-2011 |
20110269719 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS - The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP). | 11-03-2011 |
20120178722 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride. | 07-12-2012 |
20120196836 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is one of the following biocides: hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine, 2,6-dimethyl-1,3-dioxan-4-yl acetate or ortho-phenylphenol or its alkali metal or ammonium salts. | 08-02-2012 |
20120283224 | CHEMICAL STRUCTURE COMPRISING PHOSPHATES WITH POLYOL SUBSTRUCTURES FOR HAIR AND SKIN COSMETICS USAGE - A composition suitable for application to hair and/or skin comprises Phosphates Esters, such as Xylitol Phosphate Esters and other Polyol Units Phosphoric Acid Esters. This composition can be used to improve or treat skin, including scalp, conditions in cosmetic or pharmaceutical products for acne, dandruff, seborrheic dermatitis and malodor and/or can be incorporate in such formulations as a coemulsifying agent or a preservative, alone or in combination to other emulsifying or preservative agents in order to increase such activities. | 11-08-2012 |
20120309718 | METHODS FOR TREATING AN INORGANIC SLURRY - A method for treating an inorganic slurry to preserve the slurry against bacterial contamination, including (I) providing a slurry in a substantially homogeneous phase, and then (II) adding to the slurry an effective amount of a composition containing: (a) a tetrakis(hydroxyorgano)phosphonium salt selected from the group consisting of tetrakis (hydroxymethyl) phosphonium sulphate, tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium nitrate and tetrakis (hydroxymethyl) phosphonium oxalate; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom and (ii) a homopolymer of an unsaturated acid; and (III) preserving the slurry against bacterial contamination, whilst avoiding instantaneous heterogeneous thickening of the slurry due to the tetrakis (hydroxyorgano) phosphonium salt. | 12-06-2012 |
20130040916 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 02-14-2013 |
20130131020 | SYNERGISTIC COMPOSITION - A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale. | 05-23-2013 |
20130225534 | METHODS FOR TREATING AN INORGANIC SLURRY - A method for treating an inorganic slurry to preserve the slurry against bacterial contamination, including (I) providing a slurry in a substantially homogeneous phase, and then (II) adding to the slurry an effective amount of a composition containing: (a) a tetrakis (hydroxyorgano) phosphonium salt selected from the group consisting of tetrakis (hydroxymethyl) phosphonium sulphate, tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium nitrate and tetrakis (hydroxymethyl) phosphonium oxalate; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom and (ii) a homopolymer of an unsaturated acid; and (III) preserving the slurry against bacterial contamination, whilst avoiding instantaneous heterogeneous thickening of the slurry due to the tetrakis (hydroxyorgano) phosphonium salt. | 08-29-2013 |
20140080792 | Treatment method for a hydrocarbon-containing system using a biocide - A method for reducing the effects of biological contamination in a hydrocarbon-containing system comprising the steps of continuously adding a formulation comprising tris(hydroxymethyl)phosphine or a tetrakis(hydroxymethyl)phosphonium salt to the system for one day or more; monitoring the efficacy of the continuous treatment by an assessment of the extent to which there is any effect on the environment that is attributable to metabolic activity of active microbes present in the system; wherein the tris(hydroxymethyl)phosphine or tetrakis(hydroxymethyl)phosphonium salt is added at a concentration of from 1 to 30 ppm based on the total volume of aqueous fluid added to the system, and wherein the formulation is added to the system at a stage to minimize incompatibility with any other chemicals that are added to the aqueous fluid. The treatment disrupts the microbial activity of active microbes in the hydrocarbon-containing system and can prevent or reduce detrimental effects arising from the presence of active microbes in the system. | 03-20-2014 |
20140080793 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS - The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP). | 03-20-2014 |
20140206653 | [Cu(thp)4]n[X]-n Compounds For The Treatment Of A Broad Range Of Human Solid Tumors, Including Refractory Tumors - Cu(I) complexes of the type [Cu(thp)4] | 07-24-2014 |
20140221318 | BIOCIDAL COMPOSITIONS AND METHODS OF USE - Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and a polymeric biguanide. The compositions are useful for controlling microorganisms in aqueous or water-containing systems. | 08-07-2014 |
20140249114 | BIOCIDAL COMPOSITIONS AND METHODS OF USE - Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and an isothiazolinone compound selected from 1,2-benzisothiazolin-3-one, 2-methyl-1,2-benzisothiazolin-3-one, and mixtures thereof. The compositions are useful for controlling microorganisms in aqueous or water-containing systems. | 09-04-2014 |
20140256686 | COMPOSITION FOR TREATING AN INORGANIC SLURRY - A composition for treating an inorganic slurry, the composition comprising: (a) a tetrakis (hydroxyorgano) phosphonium salt; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom, (ii) a phosphonated oligomer of an unsaturated acid, (iii) a homopolymer of an unsaturated acid, and (iv) a polyphosphate. | 09-11-2014 |
20140315864 | ASSOCIATION OF MILIACIN AND POLAR LIPIDS, PARTICULARLY SPHINGOLIPIDS AND/OR PHOSPHOLIPIDS, FOR HAIR AND SCALP CARE - The present disclosure relates to a cosmetic or dietary composition for combating human or animal hair loss and/or promoting hair growth and/or regrowth and/or enhancing the beauty thereof (shine, softness, strength) and/or enhancing scalp comfort, comprising at least miliacin in a proportion greater than 0.1% by mass with respect to the total mass of the composition and polar lipids in a proportion greater than 0.1% by mass with respect to the total mass of the composition, including sphingolipids, particularly ceramides and/or glycosylceramides, and/or phospholipids in a proportion greater than 0.1% by mass with respect to the total mass of the composition. | 10-23-2014 |
20140349976 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS - As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. | 11-27-2014 |
20150038470 | BIOCIDE COMPOSITIONS - Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. | 02-05-2015 |
20150038471 | PROCESS FOR PREVENTING OR MITIGATING BIOFOULING - Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some embodiments, may also inhibit biofouling. | 02-05-2015 |
20150141377 | SYNERGISTIC COMPOSITION - A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale. | 05-21-2015 |
20160145296 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF - The present invention relates to compounds of Formula (IA) and Formula (IB), | 05-26-2016 |
20160150791 | SYNERGISTIC ANTIMICROBIAL COMPOSITION | 06-02-2016 |
20160198719 | SYNERGISTIC ANTIMICROBIAL COMPOSITION | 07-14-2016 |
20160250235 | CALCIUM GLYCEROPHOSPHATE FOR TREATING AND PREVENTING RESPIRATORY DISEASES OR CONDITIONS | 09-01-2016 |
20160374346 | BIOCIDE COMPOSITIONS - Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. | 12-29-2016 |
514130000 | The oxygen is bonded directly to a benzene ring | 12 |
20080214508 | Methods of Administering Water-Soluble Prodrugs of Propofol - A method of administering a prodrug of propofol, preferably O-phosphonooxymethyl propofol disodium salt, comprises the subcutaneous or rectal administration of the prodrug in amounts sufficient to induce or maintain a generalized anesthetized state, a conscious sedated state, or to treat insomnia, anxiety, nausea, vomiting, pruritus, epilepsy, and a range of pain syndromes, including migraine pain, and other medical conditions. | 09-04-2008 |
20080214509 | Methods for enhancing the efficacy of vascular disrupting agents - This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Antagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF-1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent. | 09-04-2008 |
20080306027 | Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof - Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: R | 12-11-2008 |
20090156562 | NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS - The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may be achieved by either varying the concentration of fluorescein, or by combining fluorescein with another dye. The invention is also directed to methods involving the use of said pharmaceutical compositions. | 06-18-2009 |
20090209496 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS - This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Receptor Tyrosine Kinase inhibitor (e.g., a small molecule RTK inhibitor, e.g., Sorafenib or Erlotinib) by administering to the subject a Vascular Disrupting Agent (e.g., a Combretastatin or derivative thereof) sequentially or simultaneously in combination with said RTK inhibitor. Pharmaceutical compositions comprising a combination of a RTK inhibitor and a VDA are also provided. | 08-20-2009 |
20090221532 | Methods Of Dosing Propofol Prodrugs For Inducing Mild To Moderate Levels Of Sedation - A dosage of a propofol prodrug needed for inducing mild to moderate sedation levels in a patient is calculated based on a patient's lean body mass. It has been discovered dosages based on gross body mass may result in overdosing, particularly for obese patients. In another aspect, a dosage suitable for inducing mild to moderate sedation levels in a patient who is at least 60 years of age is determined. A weight-appropriate dosage for the patient is determined and then adjusted by an age-based factor. For example, the dosage needed to produce a sedated state or other effect in a patient who is 60 years of age or older may be about 0.6-0.8 times the dosage needed to produce a corresponding effect in a younger patient of the same weight. | 09-03-2009 |
20090253659 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor - The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. | 10-08-2009 |
20110245207 | METHOD FOR MODERATELY INCREASING THE PROTON CONDUCTIVITY OF BIOLOGICAL MEMBRANES WITH THE AID OF MITOCHONDRIA-TARGETED DELOCALIZED CATIONS - The invention relates to biology and medicine, in particular, can be used in medicine for preparation of a pharmaceutical composition for specific, self-regulating uncoupling of mitochondria. The invention may be useful in treatment of diseases and conditions associated with violation of cellular metabolism, in treatment of obesity including its pathological forms, as well as in treatment of diseases associated with increased formation of free radicals and reactive oxygen species. In addition, the invention may be used in biotechnology for stimulation of growth of yeast and microorganisms as well as for stimulation of development of tissues and organs of plant and animal origin. | 10-06-2011 |
20120220554 | Combretastatins for Prevention of Posterior Capsule Opacification - Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification. | 08-30-2012 |
20120322769 | METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein. | 12-20-2012 |
20140142067 | TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto. | 05-22-2014 |
20140142068 | TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto. | 05-22-2014 |